vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and FOSTER L B CO (FSTR). Click either name above to swap in a different company.

Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $160.4M, roughly 1.1× FOSTER L B CO). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 25.1%). Over the past eight quarters, FOSTER L B CO's revenue compounded faster (13.6% CAGR vs 10.6%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Foster L B Co. is a U.S.-headquartered industrial manufacturing firm that develops, produces and distributes engineered access solutions, construction components, and rail infrastructure products. It serves commercial construction, transportation, and industrial end markets across North America and selected international regions.

ESPR vs FSTR — Head-to-Head

Bigger by revenue
ESPR
ESPR
1.1× larger
ESPR
$168.4M
$160.4M
FSTR
Growing faster (revenue YoY)
ESPR
ESPR
+118.6% gap
ESPR
143.7%
25.1%
FSTR
Faster 2-yr revenue CAGR
FSTR
FSTR
Annualised
FSTR
13.6%
10.6%
ESPR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESPR
ESPR
FSTR
FSTR
Revenue
$168.4M
$160.4M
Net Profit
$2.4M
Gross Margin
19.7%
Operating Margin
50.6%
4.9%
Net Margin
1.5%
Revenue YoY
143.7%
25.1%
Net Profit YoY
1098.3%
EPS (diluted)
$0.32
$0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
FSTR
FSTR
Q4 25
$168.4M
$160.4M
Q3 25
$87.3M
$138.3M
Q2 25
$82.4M
$143.6M
Q1 25
$65.0M
$97.8M
Q4 24
$69.1M
$128.2M
Q3 24
$51.6M
$137.5M
Q2 24
$73.8M
$140.8M
Q1 24
$137.7M
$124.3M
Net Profit
ESPR
ESPR
FSTR
FSTR
Q4 25
$2.4M
Q3 25
$-31.3M
$4.4M
Q2 25
$-12.7M
$2.9M
Q1 25
$-40.5M
$-2.1M
Q4 24
$-242.0K
Q3 24
$-29.5M
$35.9M
Q2 24
$-61.9M
$2.8M
Q1 24
$61.0M
$4.4M
Gross Margin
ESPR
ESPR
FSTR
FSTR
Q4 25
19.7%
Q3 25
22.5%
Q2 25
21.5%
Q1 25
20.6%
Q4 24
22.3%
Q3 24
23.8%
Q2 24
21.7%
Q1 24
21.1%
Operating Margin
ESPR
ESPR
FSTR
FSTR
Q4 25
50.6%
4.9%
Q3 25
-11.4%
6.0%
Q2 25
8.6%
5.3%
Q1 25
-34.0%
-2.0%
Q4 24
-6.4%
2.4%
Q3 24
-31.0%
5.3%
Q2 24
3.5%
3.2%
Q1 24
52.5%
4.5%
Net Margin
ESPR
ESPR
FSTR
FSTR
Q4 25
1.5%
Q3 25
-35.9%
3.1%
Q2 25
-15.4%
2.0%
Q1 25
-62.2%
-2.2%
Q4 24
-0.2%
Q3 24
-57.2%
26.1%
Q2 24
-83.9%
2.0%
Q1 24
44.3%
3.6%
EPS (diluted)
ESPR
ESPR
FSTR
FSTR
Q4 25
$0.32
$0.22
Q3 25
$-0.16
$0.40
Q2 25
$-0.06
$0.27
Q1 25
$-0.21
$-0.20
Q4 24
$-0.14
$-0.04
Q3 24
$-0.15
$3.27
Q2 24
$-0.33
$0.26
Q1 24
$0.34
$0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
FSTR
FSTR
Cash + ST InvestmentsLiquidity on hand
$167.9M
$4.3M
Total DebtLower is stronger
$42.6M
Stockholders' EquityBook value
$-302.0M
$175.3M
Total Assets
$465.9M
$330.4M
Debt / EquityLower = less leverage
0.24×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
FSTR
FSTR
Q4 25
$167.9M
$4.3M
Q3 25
$92.4M
$3.4M
Q2 25
$86.1M
$4.2M
Q1 25
$114.6M
$2.6M
Q4 24
$144.8M
$2.5M
Q3 24
$144.7M
$3.1M
Q2 24
$189.3M
$4.0M
Q1 24
$226.6M
$3.1M
Total Debt
ESPR
ESPR
FSTR
FSTR
Q4 25
$42.6M
Q3 25
$58.6M
Q2 25
$81.4M
Q1 25
$82.3M
Q4 24
$46.8M
Q3 24
$68.4M
Q2 24
$87.0M
Q1 24
$77.9M
Stockholders' Equity
ESPR
ESPR
FSTR
FSTR
Q4 25
$-302.0M
$175.3M
Q3 25
$-451.4M
$174.8M
Q2 25
$-433.5M
$174.4M
Q1 25
$-426.2M
$170.8M
Q4 24
$-388.7M
$178.3M
Q3 24
$-370.2M
$181.9M
Q2 24
$-344.2M
$147.1M
Q1 24
$-294.3M
$144.6M
Total Assets
ESPR
ESPR
FSTR
FSTR
Q4 25
$465.9M
$330.4M
Q3 25
$364.0M
$333.9M
Q2 25
$347.1M
$349.9M
Q1 25
$324.0M
$342.8M
Q4 24
$343.8M
$334.6M
Q3 24
$314.1M
$344.5M
Q2 24
$352.3M
$333.3M
Q1 24
$373.1M
$326.4M
Debt / Equity
ESPR
ESPR
FSTR
FSTR
Q4 25
0.24×
Q3 25
0.33×
Q2 25
0.47×
Q1 25
0.48×
Q4 24
0.26×
Q3 24
0.38×
Q2 24
0.59×
Q1 24
0.54×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
FSTR
FSTR
Operating Cash FlowLast quarter
$45.2M
$22.2M
Free Cash FlowOCF − Capex
$19.8M
FCF MarginFCF / Revenue
12.3%
Capex IntensityCapex / Revenue
0.0%
1.5%
Cash ConversionOCF / Net Profit
9.18×
TTM Free Cash FlowTrailing 4 quarters
$25.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
FSTR
FSTR
Q4 25
$45.2M
$22.2M
Q3 25
$-4.3M
$29.2M
Q2 25
$-31.4M
$10.4M
Q1 25
$-22.6M
$-26.1M
Q4 24
$-35.0M
$24.3M
Q3 24
$-35.3M
$24.7M
Q2 24
$-7.2M
$-5.0M
Q1 24
$53.8M
$-21.4M
Free Cash Flow
ESPR
ESPR
FSTR
FSTR
Q4 25
$19.8M
Q3 25
$26.4M
Q2 25
$7.7M
Q1 25
$-28.7M
Q4 24
$22.3M
Q3 24
$-35.5M
$21.7M
Q2 24
$-7.3M
$-7.0M
Q1 24
$53.8M
$-24.2M
FCF Margin
ESPR
ESPR
FSTR
FSTR
Q4 25
12.3%
Q3 25
19.1%
Q2 25
5.4%
Q1 25
-29.4%
Q4 24
17.4%
Q3 24
-68.7%
15.8%
Q2 24
-9.9%
-5.0%
Q1 24
39.0%
-19.4%
Capex Intensity
ESPR
ESPR
FSTR
FSTR
Q4 25
0.0%
1.5%
Q3 25
0.0%
2.0%
Q2 25
0.0%
1.9%
Q1 25
0.0%
2.6%
Q4 24
0.0%
1.5%
Q3 24
0.3%
2.2%
Q2 24
0.1%
1.5%
Q1 24
0.1%
2.2%
Cash Conversion
ESPR
ESPR
FSTR
FSTR
Q4 25
9.18×
Q3 25
6.70×
Q2 25
3.61×
Q1 25
Q4 24
Q3 24
0.69×
Q2 24
-1.74×
Q1 24
0.88×
-4.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

FSTR
FSTR

Rail Technologies And Services Segment$98.0M61%
Over Time Output Method$26.3M16%
Services$19.4M12%
Rail Technologies Products$10.0M6%
Over Time Input Method$8.3M5%

Related Comparisons